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The study examines age-dependent changes of kynurenic acid (KYNA) content and kynurenine aminotransferases (KAT I and
KAT II) celluar expression in the retinas of DBA/2J mice. Retinas were obtained from DBA/2J mice of diﬀerent ages (3, 6 and 11
months). C57BL6 mice were used as controls. As measured with HPLC, KYNA content decreased (p < 0:01) in the retinas of 6-
month-old DBA/2J mice and continued to decrease (p < 0:0074) in the retinas of 11-month-old animals compared to the controls.
Immunohistochemistry showed that expression of both KAT I and KAT II decreased markedly in the retinas of 11-month-old
DBA/2J mice compared to controls. The impairment in KYNA biosynthesis in the retinas of DBA/2J mice may be one of the
mechanisms of retinal neurodegeneration related to ocular hypertension.
 2003 Elsevier Ltd. All rights reserved.
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The tryptophan metabolite kynurenic acid (KYNA)
is the only known endogenous broad spectrum antago-
nist of all subtypes of ionotropic glutamate receptors
(Perkins & Stone, 1982). It is preferentially active at the
glycine allosteric site of the N-methyl-D-aspartate
(NMDA) receptor (Birch, Grossman, & Hayes, 1988). It
has been also demonstrated that KYNA is a noncom-
petitive antagonist of a7 nicotinic receptor (Hilmas
et al., 2001).* Corresponding author. Address: Department of Pathophysiology
of Vision and Neuro-Ophthalmology, Division of Experimental
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doi:10.1016/j.visres.2003.11.003KYNA has been detected in urine, serum, amniotic
ﬂuid (Milart, Urbanska, Turski, Paszkowski, & Sikor-
ski, 1999), cerebrospinal ﬂuid (Swartz, Matson, Mac-
Garvey, Ryan, & Beal, 1990), and brain tissue (Swartz
et al., 1990; Turski et al., 1988). Recently, KYNA has
been identiﬁed and quantiﬁed in the rat and chicken
retina (Rejdak et al., 2001, 2002) in concentrations
similar to those observed in the rat, rabbit and human
brain (Moroni, Russi, Lombardi, Beni, & Carla, 1988;
Turski et al., 1988).
In the mammalian brain, KYNA is formed by irre-
versible transamination of L-kynurenine by kynurenine
aminotransferases (KAT I and KAT II) (Guidetti, Ok-
uno, & Schwarcz, 1997). KAT I has been localized im-
munohistochemically in the rat brain, medulla and
spinal cord (Du et al., 1992; Kapoor, Okuno, Kido, &
Kapoor, 1997; Knyihar-Csillik, Okuno, & Vecsei, 1999;
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KAT II was ﬁrst identiﬁed by Northern Blot mRNA
analysis in the human brain (Okuno, Nakamura, &
Schwarcz, 1991).
Immunohistochemical experiments using KAT I and
KAT II antibodies (Okuno et al., 1991; Okuno, Tsu-
jimoto, Nakamura, & Kido, 1993) showed that both
enzymes are present in the rat inner retina. KAT I is
preferentially expressed in M€uller cell endfeet, while
KAT II is localized in cells within the ganglion cell layer
(Rejdak et al., 2001). Additionally, developmental
changes of KYNA content in both vascularised rat and
avascular chicken retinas during ontogeny have been
reported (Rejdak et al., 2002). Moreover, our recent
study also showed ontogenic changes of KAT I enzy-
matic activity in the chicken retina (Rejdak et al.,
2003b). Results of both studies suggested a neuromod-
ulatory role of KYNA in retinal ontogeny (Rejdak
et al., 2002; Rejdak et al., 2003b).
Investigations of KYNA are of importance because
KYNA has been shown to prevent neuronal damage
caused by hypoxia or ischemia (Andine et al., 1988). It
has been suggested that KYNA is involved in the
pathophysiology of several brain disorders, e.g. Par-
kinson’s disease (Ogawa et al., 1992), Huntington’s
disease (Beal, Ferrante, Swartz, & Kowall, 1991a; Beal
et al., 1991b; Guidetti, Reddy, Tagle, & Schwarcz,
2000), and epilepsy (Yamamoto, Murakami, Horiguchi,
& Egawa, 1995). Recently, it was suggested that KYNA
deﬁciency is causally related to the pathology of exci-
totoxic retinal diseases and that NMDA-induced retinal
ganglion cell (RGC) loss may cause alterations of
KYNA content in the rat retina (Rejdak et al., 2003a).
The loss of RGC is a hallmark of many ophthalmic
diseases, including glaucoma, retinal ischemia and optic
neuropathy (Dreyer, Pan, Storm, & Lipton, 1994). The
mechanisms of RGC death in those disorders are mul-
tifactorial, with a number of known risk factors (Quig-
ley, 1998). The DBA/2J mouse is a promising animal
model of ocular hypertension (John et al., 1998;
Schuettauf, Quinto, Naskar, & Zurakowski, 2002). Mice
of this strain spontaneously develop essential iris atro-
phy, pigment dispersion, and glaucomatous changes
over time (Chang et al., 1999; John et al., 1998). Pigment
dispersion and iris stroma atrophy are caused by distinct
mutations in genes encoding melanosomal proteins
(Anderson et al., 2002). Importantly, Schuettauf and
colleagues reported a continuous loss of RGC during
aging in this strain of mice (Schuettauf et al., 2002). The
authors have also found that this murine glaucoma
model is responsive to pharmacological treatments:
RGC loss was blocked by the glutamate antagonist
memantine given intraperitoneally, and by the b-blocker
timolol applied as eye drops.
Since dysfunction of KYNA synthesis in the brain
may be an important factor contributing to neuronaldegeneration (Foster, Vezzani, French, & Schwarcz,
1984; Schwarcz et al., 1992), and NMDA antagonists
prevent RGC loss in DBA/2J mice (Schuettauf et al.,
2002), we propose that KYNA and its synthesizing en-
zymes may have relevance for the mechanisms of retinal
degeneration in DBA/2J mice.
To verify this hypothesis, we examined changes of
KYNA content and KAT I and KAT II cellular
expression in the retina of DBA/2J mice during aging.2. Methods
2.1. Animals
All experiments were performed in compliance with
the guidelines of animal care in the European Commu-
nity and the Association for Research in Vision and
Ophthalmology. Female DBA/2J mice were housed with
acidiﬁed water and special chow (ssniﬀ M, Sniﬀ Spezi-
aldi€aten, Soest, Germany), and a 24 h light/dark cycle
was maintained.
2.2. Tissue preparation
Retinas from female DBA/2J mice at 3, 6 and 11
months were used in this study. Retinas from female
C57BL6 mice were used as age-matched controls. Ani-
mals were sacriﬁced with CO2, and the eyes were enu-
cleated immediately. Following hemisection of the eyes
along the ora serrata, the corneas, lenses and vitreous
bodies were removed. To assay KYNA concentration,
whole neural retinas were dissected free from the retinal
pigment epithelium, choroid and sclera. Retinas were
frozen immediately in liquid nitrogen after removal. For
immunohistochemistry, the eyecups were immersion-
ﬁxed for 30 min in 4% (w/v) paraformaldehyde in
phosphate buﬀer (PB; 0.1 M pH 7.4) at 4 C. After
washing in PB, tissues were cryoprotected by immersion
in 30% (w/v) sucrose in PB overnight at 4 C. Samples
were then embedded in cryomatrix (Leica, Heidelberg,
Germany).
2.3. HPLC
KYNA levels were investigated according to the
method of Turski and colleagues (Turski et al., 1988).
Specimens were sonicated in 2 vols (w/v) of distilled
water, immersed in a boiling water bath for 10 min and
centrifuged (10 min, 20 000 rpm). The resulting super-
natant was diluted (1:1) with 0.2 N HCl and applied to a
Dowex 50-W hydrogen form pre-washed with 0.1 N
HCl. Columns were subsequently washed with 1 ml 0.1
N HCl and 1 ml water. KYNA was eluted with 2 ml of
water. The elute was subjected to HPLC and KYNA
was detected ﬂuorimetrically according to the method of
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Fig. 1. Changes in KYNA contents in the retinas of DBA/2J mice at
the ages of 3, 6 and 11 months in comparison to age-matched controls.
Each column represents the mean KYNA concentration (pmol/g wt
wet ±SE). White column––control, black––DBA/2J mice. () Signiﬁ-
cantly diﬀerent KYNA content at 6 and 11 months when compared to
the controls (p < 0:05 for each) by unpaired t-test.
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obtained from Baker (Griesheim, Germany) and were of
the highest available purity. Statistical analysis was
performed using the unpaired Student’s t-test.
2.4. Immunohistochemistry
Embedded eye cups were cut radially in 10–12 lm
sections using a cryostat, collected on gelatine-coated
slides, air dried, and stored at )20 C for further use.
Sections were incubated for 1 h with 20% normal goat
serum (NGS; Sigma, Munich, Germany) and 0.3%
Triton X-100 in phosphate-buﬀered saline (PBST) to
reduce background staining. The primary antibodies
were diluted in PBST containing 20% NGS+2% bovine
serum albumine (Sigma). For immunohistochemistry,
sections were incubated with KAT I or KAT II antibody
diluted 1:50 overnight at 4 C. KAT I polyclonal anti-
body was raised in rabbits against rat kidney KAT I
(Okuno et al., 1991), and KAT II polyclonal antibody
was raised in rabbits against human liver KAT II (Ok-
uno et al., 1993). An anti-rabbit secondary antibody
(Molecular Probes) conjugated to Alexa 568 and diluted
1:1000 was used to mark the immunoreaction of KAT I
and KAT II antibodies. Controls were made by omitting
the ﬁrst antibody.Fig. 2. Immunoreactivity of KAT I and KAT II in radial sections of
the DBA/2J mice retina. KAT I is expressed in M€uller cell endfeet
(triangles¼M€uller cell endfeet). Intensity of KAT I immunoreaction is
the same in 3-month-old controls (A1) and DBA/2J mice (A2). At the
age of 11 months, retinal KAT I expression in control mice is the same
as in 3-month-old animals (A1, B1); however, immunoreactivity is
clearly reduced in 11-month-old DBA/2J mice (B2). At the age of 3
months, KAT II is expressed in the M€uller cell endfeet (white triangles)
and cell bodies within the GCL (arrows) in the retinas of both DBA/2J
mice (C2) and the controls (C1). Intensity of KAT II immunoreaction
is the same in 3-month-old controls (C1) and DBA/2J mice (C2). At
the age of 11 months, KAT II expression in control mice is the same as
in 3-month-old animals (D1, C1) but is clearly reduced in 11-month-
old DBA/2J mice (D2). White asterisks indicate unspeciﬁc staining of
vessels. Scale bar¼ 20 lm.3. Results
3.1. HPLC
KYNA concentrations in the mouse retina were in
the same range as that observed in rats and chickens
(Rejdak et al., 2001).
The KYNA content in the retinas of 3-month-old
DBA/2J mice was 99± 6 pmol/g wet weight (mean±SE;
n ¼ 9) and similar to that of the controls (109.5 ± 12;
n ¼ 8). In the retinas of 6-month-old DBA/2J mice it
was found to be signiﬁcantly lower (p < 0:01) compared
to controls, 75 ± 7 (n ¼ 8) and 108.7 ± 9 (n ¼ 8) respec-
tively. KYNA levels decreased at later ages in compar-
ison to those in the C57BL6 mice (p < 0:01), reaching a
concentration of 53± 10 in the retinas of 11-month-old
animals (Fig. 1).
3.2. Immunohistochemistry
Immunoreactivity of both KAT I and KAT II was
present in the inner retinas of DBA/2J mice as well as in
those of the controls at the age of 3 months (Fig. 2A1,
A2, C1, C2). KAT I immunoreactivity was mainly
concentrated vitread the cell bodies in the ganglion cell
layer in elements showing the morphological charac-
teristics of M€uller cells endfeet (see also Rejdak et al.,
2001; Rejdak et al., 2003b) (Fig. 2A1 and A2). KAT I
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11-month-old DBA/2J mice (Fig. 2B2) but not in their
age-matched controls (Fig. 2B1).
KAT II was expressed with similar intensity in cells in
the ganglion cells layer of both DBA/2J mice and con-
trols at the age of 3 months (Fig. 2C1 and C2). These
results were in agreement with our previous data ob-
tained from adult rat retina (Rejdak et al., 2001). In
parallel to KAT I, a decrease of retinal KAT II immu-
noreactivity was observed in 11-month-old DBA/2J
mice when compared to their age-matched controls (Fig.
2D1 and D2).4. Discussion
With their spontaneously developing ocular hyper-
tension and time-dependent RGC loss, DBA/2J mice are
a promising animal model for studying the consequences
of chronic elevation of IOP (Schuettauf et al., 2002).
The present study demonstrated that parallel to this
time-dependent RGC loss, KYNA concentration chan-
ges in the retinas of DBA/2J mice during aging. Retinal
KYNA contents found in both C57BL6 and DBA/2J
mice in early stages (3 months) were in the same range as
those observed in rat and chicken retinas (Rejdak et al.,
2002). The presence of KAT I and KAT II in the inner
retina in both strains of mice was also demonstrated.
In retinas of 3-month-old DBA/2J mice, KYNA
concentrations were similar to those observed in the
control animals. A marked decrease of KYNA level was
observed in retinas of 6-month-old animals, and it had
decreased to 60% of control values by the 11th month of
life. In contrast, the level of KYNA in C57BL6 mice did
not change in 3-, 6- and 11-month-old animals.
It is now assumed that KYNA contents reﬂect its
synthesis, since its storage in the brain has not been
documented (Turski, Gramsbargen, Traitler, & Schw-
arcz, 1989).
In 1998, John et al. documented that the development
of anterior segment anomalies resulted in an increase of
intraocular pressure (IOP), causing the death of retinal
ganglion cells, optic nerve atrophy, and optic nerve
cupping in DBA/2J mice. The prevalence and severity of
these lesions increased with age. The retinas of young 3-
month-old DBA/2J mice had normal morphologic fea-
tures that were similar to those observed in other mouse
strains. As glaucoma developed, the nerve ﬁber layer
became thinner. The ganglion cell layer (GCL) was the
most susceptible to cell loss, which appeared to increase
with age. In advanced cases the number of physiologi-
cally appearing ganglion cells was greatly depleted (John
et al., 1998). Recently, it has been documented that this
cell loss in a DBA/2J mice is age-dependent and starts in
the sixth month of life (Schuettauf et al., 2002). By 11
months, optic nerve atrophy and disorganization wereevident, and in 19-month-old DBA/2J optic nerves there
was a marked reduction in the number of nerve ﬁbers
(John et al., 1998). According to Savinova et al. (2001),
IOP values in the DBA/2J mice at the age of 2–6 months
are approximately 12 mmHg (during the day) and
approximately 14 mmHg (during the night), which is
markedly lower than the values found in a number of
other murine strains which do not develop glaucoma or
any other ocular abnormality (including, inter alia,
CBA/CaJ mice with the highest IOP values of all strains
tested, >20 mmHg). RGC loss in 6-month-old and
younger DBA/2J mice may therefore, precede the rise in
the intraocular pressure.
Comparing our data with those demonstrated by
other authors we found that KYNA was decreased by
24% from age 3 months to age 6 months, and by 46%
until age 11 months. Schuettauf and colleagues found
that RGC numbers decreased by 16% from age 3
months to age 6 months and by 56% until age 9 months
(Schuettauf et al., 2002). Also, NFL thickness decreased
in older DBA/2J mice but authors did not include
measurements on NFL thickness, just qualitative state-
ments without clear age correlation (John et al., 1998).
Since it has already been suggested that KYNA
deﬁciency is causally related to the pathology of exci-
totoxic brain diseases (Schwarcz, 1992), the decrease in
retinal KYNA synthesis might be considered as a con-
tributing factor in the mechanisms of RGC loss, inde-
pendently of increased IOP.
In agreement with our HPLC ﬁndings, the present
study also demonstrated that cellular expression of both
KAT I and KAT II in the inner retina decreases more
during the aging of DBA/2J mice than in control ani-
mals. Since immunohistochemical studies have shown a
preferential localization of KAT I and KAT II on
M€uller cell endfeet and RGC respectively (Rejdak et al.,
2001; Rejdak et al., 2004), it appears that KAT mal-
function leads to KYNA loss and this leads to one part
of the RGC loss. Later in age, the process of RGC
death exceeds the decrease of KYNA, and percentage of
RGC loss is bigger than the reduction of KYNA pro-
duction.
Glutamate has been shown to diminish KYNA syn-
thesis, and it has been suggested that it has a regulatory
inﬂuence on endogenous KYNA content (Urbanska,
Kocki, Saran, Kleinrok, & Turski, 1997). Since that
time, reports of increased glutamate in the vitreous in
spontaneous disorders similar to glaucoma in dogs
(Brooks, Garcia, Dreyer, Zurakowski, & Franco-Bour-
land, 1997), and quail (Dkhissi et al., 1999), and in the
aqueous of rats after optic nerve crush (Yoles &
Schwartz, 1998) have been published. It is conceivable
that the decrease of KYNA synthesis in the retina of
DBA/2J mice during aging observed in our study may be
the result of increased glutamatergic transmission, but
this remain to be determined.
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foundly not only in response to a lesion but also during
and after seizure activity (Wu & Schwarcz, 1996), as a
result of energy deprivation, and in dystonia (Richter,
Loscher, Baran, & Gramer, 1996). In several of these
instances, these changes may aﬀect the function of glu-
tamate receptors.
The endogenous glutamate antagonist KYNA has
been shown to prevent excitotoxic neuronal damage
(Andine et al., 1988; Foster et al., 1984). Neuroprotec-
tive properties of KYNA are usually explained by its
ability to block glutamate receptor functions. It has
been found that an increase in brain KYNA concen-
tration either directly, or through enhanced KYNA
synthesis may be neuroprotective. In experimental brain
ischemia neuroprotection has been observed following
systemic administration of KYNA (Andine et al., 1988),
L-kynurenine (Nozaki & Beal, 1992) as well as kynu-
renine-3-hydroxylase inhibitors (Cozzi, Carpenedo, &
Moroni, 1999; Moroni, Cozzi, Peruginelli, Carpenedo,
& Pellegrini-Giampietro, 1999). Importantly, systemic
L-kynurenine administration partially protects against
NMDA-induced degeneration of brain neurons (Nozaki
& Beal, 1992) and retinal ganglion cells, and reduces
visual discrimination deﬁcits in adult rats (Vorwerk,
Kreutz, Dreyer, & Sabel, 1996).
In conclusion, KYNA content decreases in the retinas
of DBA/2J mice during aging. This phenomenon is
accompanied by a decrease of KAT I and KAT II cel-
lular expression. Our results suggest that KYNA deﬁ-
ciency and decreased cellular expression of its
synthesizing enzymes may have relevance for the
mechanisms of retinal degenerative diseases such as
glaucoma or optic neuropathies. Further studies are
needed to determine whether the decrease in retinal
KYNA synthesis is the cause or the eﬀect of neurode-
generation in the retina.Acknowledgements
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